論文・出版
Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: a subgroup analysis of data from the Safari study (JBCRG-C06)
Misato Masuyama, Norikazu Masuda, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Cancer Medicine. 2023;00:1–13.
hhttp://doi: 10.1002/cam4.6390.
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer
Ann H Partridge, Samuel M Niman, Monica Ruggeri, Fedro A Peccatori, Hatem A Azim Jr, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B Sætersdal, Judith R Kroep, Audrey Mailliez, Ellen Warner, Virginia F Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E Lee, Janice M Walshe, Manuel Ruíz-Borrego, Halle C F Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, Karen L Smith, Teresa Ferreiro, Karin Ribi, Kathryn Ruddy, Roswitha Kammler, Sarra El-Abed, Giuseppe Viale, Martine Piccart, Larissa A Korde, Aron Goldhirsch, Richard D Gelber, Olivia Pagani; International Breast Cancer Study Group; POSITIVE Trial Collaborators
N Engl J Med, 2023 May; 388:1645-56.
https://www.nejm.org/doi/full/10.1056/NEJMoa2212856
Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
Hideko Yamauchi, Masakazu Toi, Shin Takayama, Seigo Nakamura, Toshimi Takano, Karen Cui, Christine Campbell, Liesbet De Vos, Charles Geyer Jr, Andrew Tutt
Breast Cancer, 2023 April; 30, 596-605.
https://doi.org/10.1007/s12282-023-01451-8
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative postmenopausal advanced breast cancer: An additional analysis of the JBCRG-C06 Safari study
Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Japanese Journal of Clinical Oncology. 2023 Mar; 53(3): 203–211
https://doi.org/10.1093/jjco/hyac184
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor‑positive/ human epidermal growth factor receptor 2‑negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group‑M07 (FUTURE trial)
Kenichi Watanabe, Naoki Niikura, Yuichiro Kikawa, Mari Oba, Kokoro Kobayashi, Hiroshi Tada, Shinji Ozaki, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, Toshitaka Okuno, Nobutaka Iwakuma, Takashi Takeshita, Takayuki Iwamoto, Hiroshi Ishiguro, Norikazu Masuda, Shigehira Saji
Breast Cancer Research and Treatment. 2023 Mar; 199: 253–263
https://doi.org/10.1007/s10549-023-06911-5
Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies Breast Cancer
Yutaka Yamamoto, Hiroyasu Yamashiro, Andreas Schneeweiss, Volkmar Müller, Oleg Gluz, Peter Klare, Bahriye Aktas, Magdolna Dank, László Büdi, Béla Pikó, László Mangel, Masakazu Toi, Satoshi Morita, Shinji Ohno
Breast Cancer. 2022 Sep; Online publish. Volume 30, pages88–100 (2023).
https://doi.org/10.1007/s12282-022-01399-1
Pertuzumab retreatment for HER2-positive advanced breast cancer: a randomized, open-label phase III study
Yutaka Yamamoto, Hiroji Iwata, Naruto Taira, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Norikazu Masuda, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Tomomi Fujisawa, Naoki Niikura, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno
Cancer Science. 2022 Jun; Online publish. 2022;113:3169–3179.
https://doi.org/10.1111/cas.15474
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial
Shigehira Saji, Naruto Taira, Masahiro Kitada, Toshimi Takano, Masahiro Takada, Tohru Ohtake, Tatsuya Toyama, Yuichiro Kikawa, Yoshie Hasegawa, Tomomi Fujisawa, Masahiro Kashiwaba,, Takanori Ishida,Rikiya Nakamura, Yutaka Yamamoto, Uhi Toh, Hiroji Iwata, Norikazu Masuda, Satoshi Morita, Shinji Ohno, Masakazu Toi
Lancet Oncology. 2022 May; 23(5): 636-649.
https://doi.org/10.1016/S1470-2045(22)00196-6
Immune microenvironment, homologous recombination deficiency and therapeutic response to neoadjuvant chemotherapy in triple negative breast cancer : Japan Breast Cancer Research Group (JBCRG)22 TR
Takayuki Ueno, Shigehisa Kitano, Norikazu Masuda, Daiki Ikarashi, Makiko Yamashita, Tomohiro Chiba, Takayuki Kadoya, Hiroko Bando, Takashi Yamanaka, Shoichiro Ohtani, Shigenori Nagai, Takahiro Nakayama, Masato Takahashi, Shigehira Saji, Kenjiro Aogi, Ravindranath M. Velaga, Kosuke Kawaguchi, Satoshi Morita, Hironori Haga, Shinji Ohno, Masakazu Toi
BMC Medicine 2022 Apr 25;20(1):136.
https://doi.org/10.1186/s12916-022-02332-1
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative breast cancer: An ad-hoc analysis of the JBCRG-C06 Safari study
Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Japanese Journal of Clinical Oncology. 2022 Feb; Online publish.
https://doi.org/10.21203/rs.3.rs-190374/v1